Cancer News

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer (12/05/2016)

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results were recently published in the Journal of Clinical Oncology. The kidneys are a pair of organs with multiple functions. Renal cell carcinoma is the most common type of … Continue reading "Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer"

Lenvima® Approved for Kidney Cancer (05/24/2016)

The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received at least one prior therapy with an anti-angiogenic agent, and is to be used in combination with the standard agent Afinitor® (everolimus). Each year … Continue reading "Lenvima® Approved for Kidney Cancer"

Cabometyx® Approved for Kidney Cancer (05/10/2016)

The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already been treated with prior anti-angiogenic therapy. Each year in the United States, more than 61,000 people are diagnosed … Continue reading "Cabometyx® Approved for Kidney Cancer"

Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide (03/15/2016)

If you are battling kidney cancer, otherwise known as renal cell carcinoma (RCC), The DART Study may be the next treatment option for you to consider. Dalantercept, in combination with axitinib, an FDA approved therapy, aims to halt the growth and spread of RCC. The DART Study is testing the safety and efficacy of dalantercept in combination with axitinib and is … Continue reading "Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide"